Shattuck Labs Announces Participation in Upcoming 22nd Annual Needham Virtual Healthcare Conference
Shattuck Labs, Inc. (NASDAQ: STTK), a clinical-stage biotech firm, announced its participation in the 22nd Annual Needham Virtual Healthcare Conference from April 17-20, 2023. The fireside chat will be held on April 19, 2023, featuring CEO Taylor Schreiber and CFO Andrew Neill, from 2:15 to 2:55 p.m. ET. The discussion will be available via live webcast and archived for 90 days. Shattuck is focused on developing bi-functional fusion proteins for treating cancer and autoimmune diseases, leveraging its proprietary ARC® platform and the SL-172154 program, currently in multiple Phase 1 trials.
- Participation in a prominent industry conference may boost visibility and investor interest.
- Showcases advancements in proprietary ARCs and GADLEN™ technologies targeting cancer treatment.
- None.
AUSTIN, TX and DURHAM, NC, April 03, 2023 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced that company management will participate in the 22nd Annual Needham Virtual Healthcare Conference being held April 17-20, 2023.
Presentation Details
Conference: Needham 22nd Annual Healthcare Conference
Format: Fireside chat with covering analyst Gil Blum, Ph.D.
Presenter: Taylor Schreiber, M.D., Ph.D., Shattuck’s Chief Executive Officer and Andrew Neill, M.B.A., Shattuck’s Chief Financial Officer
Date: April 19, 2023
Time: 2:15-2:55 p.m. ET
A live webcast of the fireside chat will be available on the Investors section of the Company’s website. A replay of the webcast will be archived for up to 90 days following the presentation date.
About Shattuck Labs, Inc.
Shattuck Labs, Inc. (NASDAQ: STTK) is a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease. Compounds derived from Shattuck’s proprietary Agonist Redirected Checkpoint, ARC®, platform simultaneously inhibit checkpoint molecules and activate costimulatory molecules with a single therapeutic. The company’s lead SL-172154 (SIRPα-Fc-CD40L) program, which is designed to block the CD47 immune checkpoint and simultaneously agonize the CD40 pathway, is being evaluated in multiple Phase 1 trials. Additionally, the company is advancing a proprietary Gamma Delta T Cell Engager, GADLEN™, platform, which is designed to bridge gamma delta T cells to tumor antigens for the treatment of patients with cancer. Shattuck has offices in both Austin, Texas and Durham, North Carolina. For more information, please visit: www.ShattuckLabs.com.
The Company intends to use the investor relations portion of its website as a means of disclosing material non-public information and for complying with disclosure obligations under Regulation FD.
Investor & Media Contact:
Conor Richardson
Vice President of Investor Relations
Shattuck Labs, Inc.
InvestorRelations@shattucklabs.com
FAQ
What is Shattuck Labs participating in on April 19, 2023?
Who will present at the Needham Conference for Shattuck Labs?
What technologies does Shattuck Labs develop?
Where can I watch the presentation from Shattuck Labs at the conference?
How long will the webcast of Shattuck Labs' presentation be available?
